The ArteraAI Prostate Test (mHSPC) is the first externally developed digital pathology algorithm being made clinically available through the Tempus ecosystem. This AI-powered test assesses a patient's ...

Distinguishing cancer cells from healthy cells is a central challenge in cancer treatment. Ideal therapies selectively kill cancer cells while leaving healthy cells healthy and able to perform their ...

The core foundation of precision medicine, and in turn, precision oncology, is a personalized approach to treatment that focuses on targeting specific molecular features that impact how cancer cells ...

Researchers with the James P. Allison Institute™ at The University of Texas MD Anderson Cancer Center have discovered a new ...

Evaluating associations between genomic classifier and digital pathology–based multi-modal AI biomarkers in oligometastatic castration-sensitive prostate cancer.

Plasma epigenomic profiling to reveal molecular correlates of response and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC). Comparative effectiveness of ...